207 related articles for article (PubMed ID: 16861948)
1. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure.
Bunnapradist S; Lentine KL; Burroughs TE; Pinsky BW; Hardinger KL; Brennan DC; Schnitzler MA
Transplantation; 2006 Jul; 82(1):102-7. PubMed ID: 16861948
[TBL] [Abstract][Full Text] [Related]
2. Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients.
Machnicki G; Ricci JF; Brennan DC; Schnitzler MA
Pharmacoeconomics; 2008; 26(11):951-67. PubMed ID: 18850764
[TBL] [Abstract][Full Text] [Related]
3. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients.
Tierce JC; Porterfield-Baxa J; Petrilla AA; Kilburg A; Ferguson RM
Clin Transplant; 2005 Dec; 19(6):779-84. PubMed ID: 16313325
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients.
Sollinger HW; Sundberg AK; Leverson G; Voss BJ; Pirsch JD
Transplantation; 2010 Feb; 89(4):446-51. PubMed ID: 20177347
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil.
Hardinger KL; Brennan DC; Lowell J; Schnitzler MA
Transpl Int; 2004 Nov; 17(10):609-16. PubMed ID: 15517170
[TBL] [Abstract][Full Text] [Related]
6. EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects.
Sabbatini M; Capone D; Gallo R; Pisani A; Polichetti G; Tarantino G; Gentile A; Rotaia E; Federico S
Fundam Clin Pharmacol; 2009 Oct; 23(5):617-24. PubMed ID: 19656208
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
Bilodeau JF; Montambault P; Wolff JL; Lemire J; Masse M
Transplant Proc; 2009 Nov; 41(9):3683-9. PubMed ID: 19917367
[TBL] [Abstract][Full Text] [Related]
8. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
Budde K; Glander P; Diekmann F; Dragun D; Waiser J; Fritsche L; Neumayer HH
Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
[TBL] [Abstract][Full Text] [Related]
9. Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients.
Cooper M; Deering KL; Slakey DP; Harshaw Q; Arcona S; McCann EL; Rasetto FA; Florman SS
Transplantation; 2009 Aug; 88(4):514-20. PubMed ID: 19696634
[TBL] [Abstract][Full Text] [Related]
10. Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome.
Vanhove T; Kuypers D; Claes KJ; Evenepoel P; Meijers B; Naesens M; Vanrenterghem Y; Cornelis T; Bammens B
Transpl Int; 2013 Aug; 26(8):813-21. PubMed ID: 23746202
[TBL] [Abstract][Full Text] [Related]
11. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial.
van Gelder T; Silva HT; de Fijter JW; Budde K; Kuypers D; Tyden G; Lohmus A; Sommerer C; Hartmann A; Le Meur Y; Oellerich M; Holt DW; Tönshoff B; Keown P; Campbell S; Mamelok RD
Transplantation; 2008 Oct; 86(8):1043-51. PubMed ID: 18946341
[TBL] [Abstract][Full Text] [Related]
12. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation.
Knoll GA; MacDonald I; Khan A; Van Walraven C
J Am Soc Nephrol; 2003 Sep; 14(9):2381-6. PubMed ID: 12937317
[TBL] [Abstract][Full Text] [Related]
14. Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium.
Kamar N; Oufroukhi L; Faure P; Ribes D; Cointault O; Lavayssiere L; Nogier MB; Esposito L; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Oct; 20(10):2231-6. PubMed ID: 16046517
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of low-dose mycophenolate mofetil therapy for Taiwanese renal transplantation patients receiving primary cyclosporine immunosuppression.
Tsai MK; Hu RH; Lee CJ; Lee PH
J Formos Med Assoc; 2002 Sep; 101(9):616-21. PubMed ID: 12645188
[TBL] [Abstract][Full Text] [Related]
16. Use of enteric-coated mycophenolate sodium in liver transplant patients with intestinal intolerance caused by mycophenolate mofetil.
Doria C; Ramirez CB; Frank AM; Vaccino S; Fraser N; Marino IR
Clin Transplant; 2009; 23(6):882-6. PubMed ID: 19573090
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study Group.
Transplantation; 1996 Mar; 61(5):722-9. PubMed ID: 8607174
[TBL] [Abstract][Full Text] [Related]
18. The Cost of Gastrointestinal Adverse Events and the Impact of Dose-Reductions/Discontinuations on Acute Rejection in Kidney Transplant Patients of Mycophenolate Mofetil-Related Compared to Enteric-Coated Mycophenolate Sodium: A Pharmacoeconomic Study.
Martinez-Mier G; Salazar-Ramirez A
Transplant Proc; 2016 Mar; 48(2):588-95. PubMed ID: 27110009
[TBL] [Abstract][Full Text] [Related]
19. The effect of mycophenolate mofetil and azathioprine dose on renal allograft outcome in the United kingdom.
Shah S; Collett D; Johnson R; Raftery M; Rudge C; Yaqoob MM
Transplantation; 2008 Oct; 86(8):1035-42. PubMed ID: 18946340
[TBL] [Abstract][Full Text] [Related]
20. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]